Nefropatia por imunoglobulina A

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357

Chinese Adults With Kidney Disease

NCT07522099

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

Fase II

NCT07375758

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135

NCT06291376 · Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Recrutando

🟢 Recrutando agora

11 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT06935357 · A Study to Learn About the Effects of Felzartamab Infusions …Recrutando

NCT07522099 · Chinese Adults With Kidney DiseaseRecrutando

NCT07375758 · A Study of MIL116 in Healthy Participants and Patients With …Recrutando

PHASE1, PHASE2

NCT06466135 · Study of WAL0921 in Patients With Glomerular Kidney DiseasesRecrutando

NCT06994845 · Study to Assess the Efficacy, Pharmacokinetics, Safety and T…Recrutando

NCT07146906 · A Study to Assess the Effects of Zigakibart on IgA Nephropat…Recrutando

NCT06797518 · Study to Evaluate the Impact of Iptacopan on Top of SOC on B…Recrutando

NCT07182227 · PS-002 for the Treatment of IgA Nephropathy in AdultsRecrutando

PHASE1, PHASE2

NCT07024563 · Study of Ravulizumab in Pediatric Participants With Primary …Recrutando

NCT07219121 · Sparsentan in Posttransplant Immunoglobulin A Nephropathy or…Recrutando

PHASE4

Outros ensaios clínicos

250 ensaios clínicos encontrados, 16 ativos.

Distribuição por fase

NCT03762850 · A Study of the Effect and Safety of Sparsentan in the Treatm…Ativo

NCT05852938 · A Study of Zigakibart in Adults With IgA NephropathyAtivo

NCT05248646 · Trial of Sibeprenlimab in the Treatment of A Nephropathy (Ig…Ativo

NCT07498335 · Study to Assess the Efficacy, Pharmacokinetics, Safety and T…Em breve

NCT07474636 · Efficacy and Safety Study of HS-10542 for IgA NephropathyEm breve

NCT05834738 · Randomized, Double-blind, Placebo-controlled, Crossover Stud…Concluído

NCT04564339 · Study of Ravulizumab in Proliferative Lupus Nephritis (LN) o…Encerrado

Ver todos no ClinicalTrials.gov

🧪 Está conduzindo uma pesquisa?

Divulgue para pacientes e familiares que acompanham esta doença.

Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações

1.258 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.258

#1

Bovine Lactoferrin Modulates Mononuclear Cell Activity in Human Palatine Tonsils.

International journal of molecular sciences2026 Mar 06

Lactoferrin (LF) is present in tears, nasal secretions, saliva, and milk and maintains mucosal homeostasis. The palatine tonsils represent the first immune tissue to recognize pathogens invading the oral cavity via Toll-like receptors (TLRs). We aimed to investigate the effects of bovine LF on tonsillar immune cells stimulated with ligands of TLR7 or TLR9, which recognize viral single-stranded RNA or bacterial unmethylated CpG DNA. Mononuclear cells isolated from palatine tonsils of patients with recurrent tonsillitis or immunoglobulin A (IgA) nephropathy were cultured with LF, TLR7, or TLR9 ligands. Under TLR7 stimulation, LF enhanced the activation of plasmacytoid dendritic cells (pDCs), T-killer cells, and B cells without inducing inflammatory cytokines. In contrast, under TLR9 stimulation, LF suppressed the activation of pDCs, myeloid dendritic cells, T-helper cells, T-killer cells, B cells, and natural killer cells, as well as the production of TNF-α and IL-6. Moreover, LF decreased the production of the B-cell activation factor (BAFF), a proliferation-inducing ligand (APRIL), and galactose-deficient IgA1, all of which are risk factors of IgA nephropathy. Overall, LF may enhance the immune response against viruses and contribute to immune tolerance against commensal bacteria in the palatine tonsils, indicating potential benefits in managing cold-like symptoms, recurrent tonsillitis, and IgA nephropathy.

#2

When haematuria is more than warfarin: lambda-predominant IgA nephropathy.

BMJ case reports2026 Feb 25

A woman in her 20s with a mechanical mitral valve replacement on long-term warfarin therapy presented with frank haematuria and acute kidney injury (AKI). The initial clinical impression was anticoagulant-related nephropathy. However, due to the persistence of urinary abnormalities, further evaluation was undertaken. Renal biopsy revealed immunoglobulin A nephropathy with lambda light chain predominance, raising concern for an underlying monoclonal gammopathy. The patient was managed conservatively with antiproteinuric therapy alone, without immunosuppression, and demonstrated favourable renal recovery. This case highlights the diagnostic importance of renal biopsy and thorough clinical reassessment in patients with haematuria and AKI, particularly in the context of anticoagulation.

#3

M2 macrophages alleviate podocyte apoptosis induced by supernatant of glomerular mesangial cells with aIgA1 via targeting UCHL1.

In vitro cellular & developmental biology. Animal2026 Jan

Immunoglobulin A (IgA) nephropathy (IgAN) is characterized by the deposition of IgA1 in the glomerular mesangium, which induces secondary glomerular and tubulointerstitial inflammation and subsequently leads to podocyte apoptosis and fibrosis. This condition often progresses to end-stage renal disease and lacks effective targeted treatment. Our study aimed to explore the role of M2 macrophage-mediated Ubiquitin C-terminal hydrolase L1 (UCHL1) expression in podocytes and its potential impact on the progression of IgAN. This study established an IgAN cellular model by exposing podocytes to aggregated IgA1 (aIgA1)-treated glomerular mesangial cells supernatants and assessed the impact of M2 macrophage polarization on UCHL1 expression and podocyte apoptosis. Additionally, we utilized siRNA technology and overexpression constructs to investigate the direct effects of UCHL1 modulation on podocyte apoptosis. The supernatant from aIgA1-treated glomerular mesangial cells significantly induced apoptosis in podocytes. Based on this, M2 macrophage polarization was induced using interleukin (IL)-4. The results showed that M2 macrophages (CD163+) effectively alleviated podocyte apoptosis by reducing the secretion of inflammatory cytokines IL-6, tumor necrosis factor (TNF)-α, and IL-1β, as well as downregulating the expression of apoptosis-related proteins. Notably, M2 macrophages (CD163+) inhibited the expression of UCHL1 in podocytes. Blockade of UCHL1 promoted podocyte proliferation, reduced apoptosis, and downregulated the protein expression of the fibrotic markers vascular endothelial growth factor and collagen type IV. Overexpression of UCHL1 reversed the protective effects of M2 macrophages on podocyte apoptosis. M2 macrophage (CD163+)-mediated UCHL1 downregulation in podocytes presents a potential therapeutic approach for IgAN by alleviating apoptosis.

#4

Observation on the short-term efficacy of telitacicept in the treatment of primary IgA nephropathy.

International urology and nephrology2026 Mar 23

Given the limitations of current Immunoglobulin A nephropathy (IgAN) therapies, this study sought to evaluate the short-term efficacy and safety of the novel agent Telitacicept, a dual inhibitor of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), in a real-world clinical setting. This study employed a single-center, retrospective, self-controlled before-after design. Twelve patients with primary IgAN on stable background therapy comprising angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) received add-on Telitacicept treatment for 6 months. Data on 24-h urinary protein excretion (24hUP) and estimated glomerular filtration rate (eGFR) were collected at baseline, 3 months, and 6 months. Urinary red blood cell count and safety-related indicators were collected at baseline and 6 months. Efficacy and safety were assessed by comparing intra-individual data across these time points. After Telitacicept treatment, 24hUP decreased at 3 and 6 months with statistical significance (p = 0.016, 0.004, respectively). The median 24hUP decreased from 1.13 g/24 h (IQR 0.62-2.24) at baseline to 0.52 g/24 h (IQR 0.26-1.33) at 3 months and was maintained at 0.51 g/24 h (IQR 0.15-1.07) at 6 months, yielding a clinical remission rate of 75.0%. Concurrently, the median eGFR increased from 61.09 mL/min/1.73 m2 at baseline to 77.44 mL/min/1.73m2 at 6 months, with statistical significance (p = 0.008), and 83.3% of patients showed renal function improvement. The median urinary red blood cell count decreased from 159.00 cells/μL to 15.00 cells/μL with statistical significance (p = 0.005), and 70.0% of patients with baseline hematuria achieved hematuria remission. The incidence of adverse events was low (4 cases), and all were mild. Non-high-density lipoprotein cholesterol (non-HDL-C) levels decreased, with statistical significance (p = 0.028), while other cardiovascular risk indicators remained stable. Add-on Telitacicept to standard supportive care may reduce proteinuria, improve renal function, and promote hematuria remission in patients with primary IgAN, with a favorable safety profile.

#5

Treatment practices, characteristics and outcome of immunoglobulin A nephropathy - a Swiss single center experience.

Frontiers in nephrology2026

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Geographic differences in disease course and treatment response are well recognized. The purpose of this analysis was to study clinical and histological characteristics, treatment practices and outcome of IgAN cases from a Swiss tertiary center. This retrospective cohort analysis identified 158 cases of adult biopsy-proven IgAN by chart review diagnosed between 1980 and 2016. Following detailed phenotyping, standard descriptive methods and univariate analysis were applied. The majority of patients was male and of European ancestry. At diagnosis, mean estimated glomerular filtration rate (eGFR) was 55.7 ml/min/1.73 m2, mean proteinuria was 2.4 g/d and 69.9% of the patients were hypertensive. Clinical presentation varied according to age. Initial biopsies showed moderate to severe tubular atrophy and interstitial fibrosis (IFTA) in 29.1% and crescents in 36.7% of cases. Therapy included renin-angiotensin-aldosterone-inhibitors in 86.7% as well as immunosuppressive therapy in 46.8% including steroids and other immunosuppressive drugs (28.7%), mainly azathioprin. Outcome included 34.1% complete and 22.2% partial remissions, relapses in 32.0% of patients, while 43.0% of patients progressed to ESKD during follow-up (median 100.0 months). Recurrence rate after transplantation was 18.8%. Immunosuppressive therapy was more frequently used in patients with higher proteinuria level, higher hematuria grade, lower eGFR, more intense IgA and complement C3 staining and crescents. Predictors of progression were higher age, lower eGFR, higher proteinuria and blood pressure as well as crescents and higher extent of IFTA on the initial biopsy. This retrospective cohort analysis gives insight into characteristics and outcome of patients with IgAN from a Swiss tertiary center, treatment practices as well as predictors of outcome and therapy choices. A comparatively high use of immunosuppressive treatment including non-steroid-based regimens was found along with a high rate of progression to ESKD.

Publicações recentes

Health Care Resource Utilization and Productivity Impairment in Adults with Immunoglobulin A Nephropathy: A Real-World, Observational, Global Analysis.

Glomerular Dis2026 Jan-Dec

Immunoglobulin A nephropathy-novel insights in long-term outcomes and pathophysiology leading to international guideline modification and new emerging therapies.

J Nephrol2026 Apr 16

Chronic kidney disease progression in glomerular diseases: is hematuria a key risk factor?

Pediatr Nephrol2026 Apr 13

The role of the lactate dehydrogenase-to-albumin ratio in predicting renal prognosis in Chinese IgA nephropathy patients: a retrospective cohort study.

Front Endocrinol (Lausanne)2026

Telitacicept Add Glucocorticoids Versus Telitacicept Alone in the Treatment of IgA Nephropathy: A Real-World Study.

FASEB J2026 Apr 30

Ver todas no PubMed

📚 EuropePMC830 artigos no totalmostrando 196

Observation on the short-term efficacy of telitacicept in the treatment of primary IgA nephropathy.

Treatment practices, characteristics and outcome of immunoglobulin A nephropathy - a Swiss single center experience.

International journal of molecular sciences

Bovine Lactoferrin Modulates Mononuclear Cell Activity in Human Palatine Tonsils.

Molecular nutrition & food research

Beneficial Effect of Xanthohumol Supplementation on the Clinical Course of IgA Nephropathy Refractory to Conventional Treatment-A Prospective, Open-Label Case Series.

The journal of vascular access

Hybrid boat-shaped and tubularized bovine patch conduit: A salvage solution for arteriovenous fistula creation.

Naunyn-Schmiedeberg's archives of pharmacology

Global research trends and hotspots in targeted therapy for IgA nephropathy: a bibliometric and visualization analysis (1999-2025).

ACSL4 mediates ferroptosis to promote immunoglobulin A nephropathy progression: scRNA-seq analysis.

Clinical medicine insights. Case reports

Immunoglobulin A Nephropathy With Associated Thrombotic Microangiopathy: Biopsy and Clinical Case Series.

Applied biochemistry and biotechnology

Ophiocordyceps indica from the Indian Himalayas Ameliorates the IgA Nephropathy in Mice.

European journal of medical research

Telitacicept alleviates IgA nephropathy by targeting PDHA1 lactylation to inhibit B cell metabolic reprogramming and lactate-mediated renal injury.

Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis.

Patient and Provider Perspectives on the Patient Journey in Immunoglobulin A Nephropathy.

Concomitant immunoglobulin A nephropathy and membranous nephropathy with Fabry-like zebra bodies: A case report and literature review.

Medicine

Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study.

Frontiers in immunology

Prognostic Significance of Lactate Dehydrogenase-to-Albumin Ratio and Neutrophil Percentage-to-Albumin Ratio in IgA Nephropathy.

Biomedicines

When haematuria is more than warfarin: lambda-predominant IgA nephropathy.

BMJ case reports

Kidney diseases (Basel, Switzerland)

The Impact of Gut Microbiota on Immunoglobulin A Nephropathy through the Mediation of Specific Immune Cells: A Mendelian Randomization Study.

Colonic Malakoplakia With an Adenomatous Appearance on Magnification Endoscopy: A Case Report.

DEN open

Outcomes and predictors of kidney failure in elderly patients with biopsy-proven IgA nephropathy.

Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.

Predicting the Course of Immunoglobulin A Nephropathy Using Urinary Soluble Cluster of Differentiation 163 as a Prognostic Biomarker.

Nephrologie & therapeutique

Effect of on-demand immunosuppressive therapy on long-term outcomes in patients with immunoglobulin A nephropathy: A real-world cohort study.

Assessing the real-world safety of sparsentan for immunoglobulin A nephropathy: insights from a comprehensive analysis of FAERS database.

Shared T-Cell Receptor Repertoire in the Tonsils of Patients with Immunoglobulin A Nephropathy.

Kidney360

Efficacy and safety of budesonide for the treatment of IgA nephropathy: a systematic review and meta-analysis.

Frontiers in pharmacology

Mechanistic insights into Shenqi Dihuang decoction in the treatment of immunoglobulin a nephropathy.

Clinical and experimental nephrology

Post-biopsy proteinuria as a universal prognostic marker across diverse clinical courses in IgA nephropathy.

Comparison of Oxford versus Japanese Histological Grading to predict renal function decline in IgA nephropathy: a Japanese prospective cohort study.

The Cutting Edge: A Clinicopathology Minireview of Immunoglobulin A Nephropathy.

Glomerular diseases

Metabolic Checkpoints in IgA Nephropathy: From Pathogenesis to Precision Medicine.

Drugs

A retrospective single-center cohort study of major subtypes of primary glomerular diseases (MN, IgAN, and MCD): clinical characteristics, prognostic outcomes, and risk factors.

Serum proteome analysis detects early molecular signatures of disease progression in IgA nephropathy.

Annual review of medicine

Immunoglobulin A Nephropathy: New Treatment Options.

Progression of immunoglobulin A nephropathy (IgAN) in a Hispanic/Latinx population in the United States.

American journal of clinical and experimental immunology

Dietary patterns, physical activity, and risk of urinary tract diseases: a two sample Mendelian randomization analysis.

Treatment patterns, clinical outcomes, and economic burden among patients with immunoglobulin A nephropathy (IgAN) in China.

Preeclampsia in Saudi Arabia: A Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Awareness, and Outcomes.

Biopsy-proven tyrosine kinase inhibitor-associated renal injury: a case series.

Predictive value of interstitial inflammation for renal outcome in patients with immunoglobulin a nephropathy.

Immunobiology

Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis.

World journal of nephrology

Prognostic value of the MEST-C score in long-term outcomes of immunoglobulin A nephropathy patients: Insights from a developing country.

The Immunoglobulin A Nephropathy Renaissance: From Pathogenesis to Personalized Therapy.

Non-Invasive Early Detection of Tubular Atrophy and Interstitial Fibrosis in Immunoglobulin A Nephropathy Using [18F] AlF-NOTA-FAPI-04 PET/CT: A Pilot Study.

Academic radiology

Colloids and surfaces. B, Biointerfaces

Integrated analysis of single-cell and bulk RNA-seq data identifies NR4A1-associated macrophages in immunoglobulin A nephropathy.

Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in Immunoglobulin A Nephropathy.

Kidney360

American journal of kidney diseases : the official journal of the National Kidney Foundation

Complement Inhibition in Immunoglobulin A Nephropathy: A Mini-Review.

American journal of translational research

Urinary exosomal miR-320b as a biomarker of tubular atrophy/interstitial fibrosis in IgA nephropathy patients.

Association of Podometric Parameters with the Oxford MEST-C Score and Pre-Treatment eGFR Slope in Patients with IgA Nephropathy.

Kidney360

Efficacy and safety of telitacicept in the treatment of immunoglobulin a nephropathy: a real-world, single-center, retrospective study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Tonsillectomy and immunosuppression improve outcomes in Caucasians with high-risk IgA-nephropathy.

Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon.

Journal of medical case reports

Diagnostic challenges in culture-negative infective endocarditis: a case of histoplasma endocarditis: a case report.

ESRRA-ATG5-Mediated mitophagy enhances arginine metabolism to alleviate diabetic kidney disease.

Autophagy

Case Report: Maximizing the anti-proteinuric response: a multicenter real-world sparsentan case series in IgA disorders.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Disease modification in immunoglobulin A nephropathy.

Trends of Biopsy-Proven Kidney Diseases in Romania: A Single-Center Registry Report Spanning 28 Years.

Crohn's Disease Presenting With Secondary Immunoglobulin A Nephropathy and Cutaneous Vasculitis: Unusual Extraintestinal Manifestations.

ACG case reports journal

Tubulointerstitial nephritis uveitis syndrome with Fanconi syndrome: Two case reports and literature review.

Medicine

Journal of inflammation research

Integrative Bulk and Single-Cell Transcriptome Analyses Reveal Mitochondrial Metabolism-Related Biomarkers in IgA Nephropathy with Experimental Validation.

Rapidly Progressive IgA Nephropathy in a Patient with Systemic Lupus Erythematosus and Chronic Hepatitis B: A Case Report.

Reports (MDPI)

In vitro cellular & developmental biology. Animal

M2 macrophages alleviate podocyte apoptosis induced by supernatant of glomerular mesangial cells with aIgA1 via targeting UCHL1.

Journal of comparative effectiveness research

Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan.

Infection and drug resistance

Case Report: A Pulmonary Cryptococcosis Presenting as Interstitial Pneumonia in a Patient of IgA Nephropathy.

Risk factors of adverse pregnancy outcomes in patients with immunoglobulin A nephropathy.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Kidney transplantation across ABO-H incompatibility in a recipient with Bombay blood group: A novel report.

Accuracy of ICD-10 coding for identifying immunoglobulin A nephropathy (IgAN) prior to 2023.

Pediatric nephrology (Berlin, Germany)

Comments on 'Retrospective analysis of glucocorticoid therapy in paediatric immunoglobulin A nephropathy: kidney outcomes and efficacy'.

Bioinformatics-based exploration of the role of copper metabolism in chronic glomerulonephritis.

Medicine

Bilateral vision loss as first clinical manifestation of IgA nephropathy.

BMC ophthalmology

Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Multiple circulating inflammatory proteins are associated with pathological lesions and kidney function decline in IgA nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers.

Dermatology online journal

Bullous pemphigoid in a patient with immunoglobulin A nephropathy.

Association between neutrophil-to-lymphocyte ratio and early renal function decline in patients with immunoglobulin a nephropathy.

Annals of medicine

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Plasmacytoid dendritic cells modulate the production of mucosal IgA in IgA nephropathy.

International journal of molecular sciences

Impact of Particulate Matter on the Exacerbation of Immunoglobulin A Nephropathy: An Animal Experimental Study.

The neutrophil-to-monocyte ratio: a superior inflammatory marker predicting poor prognosis in IgA nephropathy.

Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.

Presence of crescents in IgA nephropathy-prediction from ultrasound images using deep learning.

BMC medical imaging

Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathway.

EMBO molecular medicine

European journal of internal medicine

Left ventricular remodeling in IgA nephropathy: Prognostic implications and clinical correlations.

Patterns of Glomerular Injury: Histopathological Classification and Clinical Correlation.

Renal survival and improvement in younger malignant hypertension patients with thrombotic microangiopathy.

Australian journal of general practice

From microscopic haematuria to kidney failure: The hidden progression of IgA nephropathy.

Telitacicept administration improved immunoglobulin A nephropathy after hematopoietic stem cell transplantation: a case report.

Effect of dapagliflozin on eGFR slope in IgA nephropathy based on renal pathological assessment using image analysis software.

Metabolism open

Diabetes, obesity & metabolism

Genetic evidence for repurposing GLP-1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti-inflammatory pathways beyond glycaemic control.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

What are the right endpoints to assess the effectiveness of new treatments for IgAN?

Novel therapies improve prognosis of IgAN and limit the applicability of the International IgA Nephropathy Prediction Tool.

KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

Kidney international

Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

Kidney international

The Journal of international medical research

Effect of dapagliflozin on proteinuria and the slope of the estimated glomerular filtration rate in patients with immunoglobulin A nephropathy: A multicenter prospective study.

Treatment of recurrent IgA nephropathy after kidney transplantation with targeted-release budesonide - a case report.

Clinical pharmacology in drug development

Comparison of the Pharmacokinetics of Three Budesonide Formulations in Healthy Chinese Subjects.

Histone methylation of kidney disease: fact or fantasy?

Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy.

MedComm

Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety.

A case of IgA nephropathy treated with a combination of telitacicept and half-dose glucocorticoids.

Open life sciences

Neisseria species on the tonsillar surface predicts favorable clinical outcomes in patients with Immunoglobulin A nephropathy who underwent tonsillectomy.

Investigating the genetic effects of metformin-related targets on IgA nephropathy using Mendelian randomization.

Quantitative imaging in medicine and surgery

Quantitative analysis of macular and optic disc microvascular parameters in patients with immunoglobulin A nephropathy using optical coherence tomography angiography.

Journal, genetic engineering & biotechnology

Integrative bioinformatics analysis unveils hub transcription factors and their interacting drugs in immunoglobulin A nephropathy: Implications for pathogenesis and treatments.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Attribute-based medicine for IgA nephropathy: risk factor constellations influence kidney prognosis.

Inflammatory and nutritional indexes as predictors of acute kidney injury in patients with Immunoglobulin A nephropathy: a retrospective study.

PeerJ

Bioinformatic analysis, clinical implications and experimental validation of ferroptosis-related feature gene in IgA nephropathy: focus on DUSP1.

Precision clinical medicine

Glycosylation in kidney diseases.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Targeted therapeutic options based on the pathogenesis of IgA nephropathy.

Association Between Surrogate Endpoints and Clinical Outcomes in Immunoglobulin A Nephropathy: A Systematic Literature Review.

Advances in therapy

Construction of LncRNA-miRNA-mRNA regulatory network in IgA nephropathy mice model by RNA-sequencing and bioinformatics analysis.

Genes & genomics

Frontiers in pharmacology

Opportunities and challenges in the treatment of IgA nephropathy.

Telitacicept treatment for recurrent IgA nephropathy after kidney transplantation.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

What do clinical trials teach us about the pathophysiology of human IgA nephropathy?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

How should we measure and interpret glomerular inflammation and what is the best anti-inflammatory approach in IgA nephropathy?

Clinical and experimental medicine

Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study.

Development of a Natural Language Processing Model for Extracting Kidney Biopsy Pathology Diagnoses.

Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients.

The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy.

Effects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy.

Efficacy and safety of complement inhibitors in IgAN: a systematic review and meta-analysis.

Internal medicine (Tokyo, Japan)

Two-year Follow-up of IgA Nephropathy Patients Who Developed Gross Hematuria Following COVID-19 Vaccination: A Case Series and Literature Review.

Therapeutic advances in rare disease

Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT study.

Developing serum proteomics based prediction models of disease progression in ADPKD.

Nature communications

Pediatric nephrology (Berlin, Germany)

Retrospective analysis of glucocorticoid therapy in pediatric immunoglobulin A nephropathy: Kidney outcomes and efficacy.

International immunopharmacology

Comprehensive analysis of B cell receptor repertoires reveals a distinct lambda light chain landscape in immunoglobulin A nephropathy.

Development and validation of personalized risk prediction models for patients with IgA nephropathy: a nationwide multicenter cohort study.

Internal medicine (Tokyo, Japan)

Successful Remission of Nephrotic Syndrome Caused by IgA Nephropathy with Membranoproliferative Glomerulonephritis-pattern Lesion Treated by Cyclosporine and Oral Corticosteroids.

Gut microbiota as a predictive tool for outcomes in IgA nephropathy.

World journal of clinical cases

Treatment of immunoglobulin A nephropathy: Current perspective and future prospects.

The combined analysis of metabolomics and transcriptomics revealed the metabolic changes of kidney tissue in mice with IgA nephropathy.

Genomics

Tonsil-induced autoimmune/inflammatory syndrome: Current insights into the pathogenic role of tonsils in immunoglobulin A nephropathy, palmoplantar pustulosis and psoriasis.

Auris, nasus, larynx

Dilemma of missing specific disease codes: an approach to assess the incidence and prevalence of a rare nephrology disease.

Deep learning-based quantitative analysis of glomerular morphology in IgA nephropathy whole slide images and its prognostic implications.

Problems and prospects of metabolomic studies in the alteration of the gut microbiome.

Biomeditsinskaia khimiia

Life (Basel, Switzerland)

Biopsy-Proven Glomerulopathies in Romania: A 10-Year Nationwide Study.

Acta pharmacologica Sinica

Acteoside-containing caffeic acid is bioactive functional group of antifibrotic effect by suppressing inflammation via inhibiting AHR nuclear translocation in chronic kidney disease.

Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

A prognostic model of immunoglobulin A nephropathy using artificial neural network: a retrospective study based on integrated Chinese and Western Medicine.

Inflammation-associated molecules in the glomerular-endothelium in mild IgA-nephropathy patients identified by single-cell and spatial transcriptome.

Communications biology

Successful hemodialysis catheter placement into a stenosed femoral vein using balloon dilation for central venous access.

Radiology case reports

Kidney international reports

The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Rapid detection of kidney disease based on urine surface-enhanced Raman spectroscopy and principal components analysis-support vector machine/random forests.

Kidney research and clinical practice

Integrated genomics and metabolomics to identify cause-specific biomarkers for chronic kidney disease in a Korean population.

Kidney Transcriptomic and Proteomic Analyses Provide New Insight into the Pathogenesis of IgA Nephropathy in Mice.

Biochemical genetics

Kidney research and clinical practice

External validation of the international immunoglobulin A nephropathy (IgAN) prediction tool in Korean children with IgAN.

Retracted: Chronic Epipharyngitis Treated with Epipharyngeal Abrasion Therapy: Symptoms, Diagnosis, Pathogenesis, and Treatment Outcomes.

JMA journal

Adult-Onset Immunoglobulin A Vasculitis (IgAV) Presenting in a Middle-Aged Indian Male Patient.

Association between different proportions of crescents and adverse renal outcomes in immunoglobulin a nephropathy: a systematic review and meta-analysis.

Annals of occupational and environmental medicine

Three cases of congenital diseases in the children of female semiconductor workers at a company recognized by the Occupational Disease Adjudication Committee.

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review.

Global & regional health technology assessment

Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data.

Journal of clinical medicine

Modern Biomarkers in IgA Nephropathy and Their Potential in Paediatric Research.

Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort.

Cell communication and signaling : CCS

IKZF1 as a potential therapeutic target for dendritic cell-mediated immunotherapy in IgA nephropathy.

Long non-coding RNA in IgA nephropathy: a comprehensive review.

[The comorbidity mechanism of celiac disease and immunoglobulin A nephropathy].

Zhonghua nei ke za zhi

Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching.

Long-term evaluation of the timing of corticosteroid therapy in an IgA nephropathy cohort.

Gut Microbiota and Immunoglobulin A Nephropathy: Exploration of Dietary Intervention and Treatment Strategies.

Food science & nutrition

Early post-treatment remission of proteinuria is associated with long-term prognosis in patients with immunoglobulin A nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

CKD progression, kidney failure, and mortality among US patients with IgA nephropathy.

Combinatorial chemistry & high throughput screening

High-Content Screening of Wind-Dampness Dispelling Traditional Chinese Medicines against Podocyte EMT Induced by IgA1.

Kidney research and clinical practice

Clinical significance of the time-average systemic immunoinflammatory index in primary immunoglobulin A nephropathy: a bicentric retrospective cohort study.

The Journal of international medical research

IgA nephropathy, non-cirrhotic portal fibrosis, and POEMS syndrome: A rare combination in the long-term follow-up of Sjögren's syndrome.

Journal of managed care & specialty pharmacy

Cost-effectiveness analysis of targeted-release formulation of budesonide (Tarpeyo) in conjunction with optimized renin-angiotensin system inhibitor (RASi) therapy relative to optimized RASi therapy alone for adults with primary immunoglobulin A nephropathy in the United States.

Celastrol modulates damage of renal tissues in Immunoglobulin A nephropathy via targeting TGase-2/HMGB1 signaling pathway.

Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review.

Pediatric Case of Crohn Disease, Immunoglobulin A Nephropathy, and Atopic Dermatitis.

Pediatrics

The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency.

eGFR slope modelling predicts long-term clinical benefit with nefecon in a real-world IgAN population.

Kidney international reports

Efficacy and Safety of Telitacicept as an Add-On Therapy for Refractory Immunoglobulin A Nephropathy or Immunoglobulin A Vasculitis Nephropathy in Children.

An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy.

Advances in therapy

Internal medicine journal

Glomerular disease registry and biobank: design and baseline results.

Journal of inflammation research

Novel Biomarkers as Non-Invasive Diagnostic Tools in IgA Nephropathy: A Comparative Study with Lupus Nephritis and Membranous Nephropathy.

Normolipidemic lipoprotein glomerulopathy with IgA nephropathy - ApoE Kyoto mutation: a case report.

Diagnostic pathology

International journal of nephrology

Characterisation of IgA Nephropathy in an Australian Cohort.

Is the association between Immunoglobulin A Nephropathy and Spondyloarthritis real? A case-based review.

ARP rheumatology

Identification of Potential Drug Targets for Immunoglobulin A Nephropathy: A Mendelian Randomization Study.

Biomedicines

Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

Immune Checkpoint Inhibitor-Related Immunoglobulin A Nephropathy in a Patient with Advanced Head and Neck Cancer.

Frontiers in endocrinology

Clinical characteristics and prognostic analysis of patients with type 2 diabetic kidney disease and non-diabetic kidney disease.

Different doses of hydroxychloroquine regulate the structure of intestinal flora and glycosyltransferase activity in rats with IgA nephropathy.

Immunobiology

Frontiers in pharmacology

Efficacy and safety of Kunxian in IgA nephropathy.

Investigation of the Relationship Between Neutrophil/Lymphocyte, Platelet/Lymphocyte, IgA/C3, IgA/C4, and C3/C4 Ratios and Proteinuria in Patients With Immunoglobulin A (IgA) Nephropathy.

Internal medicine (Tokyo, Japan)

Immunoglobulin A Nephropathy in a Kidney Transplant Recipient with Kabuki Syndrome.

Prognostic nutritional index as an independent risk factor for disease progression in patients with IgA nephropathy.

Journal of medical Internet research

Risk Stratification in Immunoglobulin A Nephropathy Using Network Biomarkers: Development and Validation Study.

Anti-nephrin antibody: a potential biomarker of minimal change disease.

Kidney international reports

Patients With Immunoglobulin A Nephropathy Show Abnormal Frequencies of B Cell Subsets, Unconventional T Cells, and High Levels of Galactose-Deficient IgA1-Coated Gut Bacteria.

Single-cell transcriptomics reveals the immune mechanisms by which tonsillectomy improves clinical outcomes of recurrent Immuoglobulin A nephropathy after kidney transplant.

Molecular immunology

Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy.

Frontiers in immunology

Kidney diseases (Basel, Switzerland)

Pharmacokinetic Aspects of Hydroxychloroquine and Its Relationship to Efficacy in Immunoglobulin A Nephropathy.

Glomerular galactose-deficient IgA1 and apoptosis inhibitor of macrophage staining in secondary IgA nephropathy associated with alcoholic cirrhosis.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Induction of immune tolerance in living related human leukocyte antigen-matched kidney transplantation: A phase 3 randomized clinical trial.

Machine learning-based unsupervised phenotypic clustering analysis of patients with IgA nephropathy: Distinct therapeutic responses of different groups.

Chinese medical journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.

Journal of physiological investigation

CircRNA-0013747 Promotes Mesangial Cell Proliferation in Immunoglobulin A Nephropathy through Modulation of the Warburg Effect.

Molecular oral microbiology

From Teeth to Body: The Complex Role of Streptococcus mutans in Systemic Diseases.

Ver todos os 830 no EuropePMC

Próxima:Associações

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Nefropatia por imunoglobulina A.

É de uma associação que acompanha esta doença? Fale com a gente →

Próxima:Comunidades

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Nefropatia por imunoglobulina A

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Próxima:Tire suas dúvidas

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Próxima:Doenças relacionadas

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Síndrome nefrótica idiopática

7 em comum

ORPHA:357502

Glomerulonefrite pauci-imune

6 em comum

ORPHA:93126

Síndrome nefrótica sensível aos esteroides

Nefropatia não-lúpica full-house idiopática

ORPHA:69061

ORPHA:567544

Glomerulopatia C3

Doença renal cística genética

ORPHA:329918

ORPHA:93587

Síndrome Alport

Doença de anticorpos antimembrana basal glomerular

ORPHA:63

Glomerulonefrite membrano-proliferativa primária

ORPHA:375

Síndrome nefrótica cortico-resistente idiopática com resistência secundária aos corticoides

ORPHA:54370